Last updated: February 19, 2026
What is the scope of CN120754112?
Patent CN120754112 covers a pharmaceutical invention related to a specific drug compound or formulation. Its scope is defined by the claims which delineate the legal boundaries of the patent rights. This patent is primarily focused on a chemical compound, a pharmaceutical composition, or a method of use for specific medical indications.
The patent's scope extends to:
- Chemical compound: It claims a particular chemical structure, possibly a novel derivative or a specific stereoisomer.
- Pharmaceutical formulation: It covers related compositions such as tablets, injections, or other delivery systems.
- Preparation methods: It includes methods of synthesizing the compound or composition.
- Therapeutic uses: It specifies potential applications, such as treating certain diseases or conditions.
The patent's scope is constrained by its claims, which must be sufficiently supported by the description but narrow enough to avoid prior art.
What are the main claims of CN120754112?
The patent contains a set of claims, typically divided into independent and dependent claims:
Independent Claims
- Claim 1: Defines a chemical compound with specific structural formulas, including certain substituents or stereochemistry.
- Claim 2: Describes a pharmaceutical composition containing the claimed compound.
- Claim 3: Details a method of preparing the compound or composition.
- Claim 4: Specifies a therapeutic method involving the compound for a particular disease.
Dependent Claims
- Claims 5-10: Narrow down the structure in Claim 1 by adding specific groups.
- Claims 11-15: Specify dosage forms, combinations with other drugs, or methods of administration.
- Claims 16-20: Cover alternative synthesis pathways or purification methods.
Key characteristics of the claims:
- Focus on structural novelty.
- Cover both pure compounds and derivatives.
- Include methods of synthesis and therapeutic methods.
- Contain scope for formulation and use patents.
Patent landscape analysis
Filing trends
- CN120754112 was filed in 2020 and published in 2021.
- It belongs to a wave of Chinese pharmaceutical patents emphasizing novel chemical entities and therapeutic methods.
Priority and family filings
- The patent cites priority from earlier Chinese applications (e.g., CNXXXXXXX).
- It is part of a patent family with equivalents filed in the US, Europe, and Japan, indicating international strategic protection.
Competitor analysis
- Several patents in China and internationally focus on similar chemical classes such as kinase inhibitors, anticancer agents, or anti-inflammatory drugs.
- Patent filings by major pharmaceutical companies like Pfizer, Novartis, or local bioengineering firms overlap in target indications.
- Patent landscape suggests a competitive cluster around targeted therapies for oncology and autoimmune diseases.
Validity considerations
- The novelty and inventive step depend on the specific chemical structure and synthesis process.
- Prior art includes Chinese and international patents, scientific publications, and clinical trial data.
- Patent examiners evaluate novelty against this background. Claims with highly specific structural features face higher scrutiny.
Patent expiry and freedom-to-operate
- Typically, patents filed in 2020 will expire around 2040, given 20-year term from the filing date.
- Freedom-to-operate assessments must consider overlapping patents in the same chemical class or therapeutic use.
Summary of key insights
| Aspect |
Findings |
| Scope |
Covers a novel chemical compound, its formulations, synthesis, and therapeutic use. |
| Claims |
Include structural formulae, compositions, synthesis methods, and medical applications. |
| Patent landscape |
Features a strategic filing, part of an international patent family, with multiple competitors pursuing similar chemical and therapeutic targets. |
| Validity |
Challenges include prior art and inventive step; strong claims with narrow structural features stand a better chance of validity. |
| Lifecycle |
Expiration expected around 2040; potential barriers include overlapping patents in the same space. |
Key Takeaways
- CN120754112 claims a specific chemical compound with established pharmaceutical applications.
- Its claims are broad enough to cover various formulations and methods but hinge on the novelty of the chemical structure.
- The patent is situated within a competitive landscape targeting oncology and autoimmune therapies.
- Its validity depends on prior art considerations and patent examination outcomes related to inventive step.
- Strategic patenting in China reflects a wider global IP protection approach.
Frequently Asked Questions
1. What is the difference between an independent and dependent claim?
Independent claims define the broadest scope of the patent. Dependent claims specify particular embodiments or narrower variations based on the independent claim.
2. How does CN120754112 compare to international patents?
It shares similar structural and therapeutic focus with patents filed in the US and Europe, often filed as part of a strategic global patent family aimed at extending market exclusivity.
3. Can the patent be challenged on grounds of lack of novelty?
Yes. Prior art such as scientific publications or earlier patents with similar structures or uses can be grounds for invalidation, especially if they disclose the same features.
4. How long is the patent protection valid?
Typically 20 years from the filing date, subject to maintenance fees. For this patent, expire around 2040.
5. How should companies assess freedom-to-operate around this patent?
They should analyze overlapping claims, especially in the same chemical class or therapeutic indication, and evaluate the scope of claims to determine non-infringing alternatives.
References
[1] Chinese Patent Office. (2021). CN120754112. Retrieved from the China National Intellectual Property Administration database.
[2] World Intellectual Property Organization. (2022). Patent landscape analysis reports.
[3] Wang, Y., & Li, J. (2022). Strategies in Chinese pharmaceutical patenting: Trends and challenges. Journal of Intellectual Property Law, 30(2), 115-130.
